pemetrexed
Showing 1 - 25 of 527
NSCLC, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis Trial (Pemetrexed)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- +2 more
- Pemetrexed
- (no location specified)
Mar 27, 2023
NSCLC Metastatic Trial (Atezolizumab, Nab paclitaxel, Carboplatin)
Not yet recruiting
- Non-Small Cell Lung Cancer Metastatic
- Atezolizumab
- +5 more
- (no location specified)
Jan 18, 2023
NSCLC Trial in Pittsburgh (Tiragolumab, Atezolizumab, Pemetrexed)
Not yet recruiting
- Non-small Cell Lung Cancer
- Tiragolumab
- +3 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Feb 16, 2023
NSCLC (NSCLC) Trial (MK-2870, Docetaxel, Pemetrexed)
Not yet recruiting
- Non-small Cell Lung Cancer (NSCLC)
- MK-2870
- +2 more
- (no location specified)
Oct 3, 2023
Primary CNS Lymphoma, Secondary CNS Lymphoma, Relapsed Cancer Trial in Miami (drug, procedure, radiation)
Not yet recruiting
- Primary Central Nervous System Lymphoma
- +3 more
- Pemetrexed
- +3 more
-
Miami, FloridaMiami Cancer Institute at Baptist Health, Inc.
Dec 23, 2022
Non Small Cell Lung Cancer, Mesothelioma Trial in Netherlands (Pemetrexed)
Recruiting
- Non Small Cell Lung Cancer
- Mesothelioma
- Pemetrexed
-
's-Hertogenbosch, Netherlands
- +4 more
Sep 9, 2022
Urothelial Carcinoma, Metastatic Cancer Trial in Houston (Pemetrexed, Zimberelimab, Etrumadenant)
Not yet recruiting
- Urothelial Carcinoma
- Metastatic Cancer
- Pemetrexed
- +2 more
-
Houston, TexasMD Anderson Cancer Center
Nov 28, 2022
Non-Small-Cell Lung Carcinoma Trial (biological, drug, dietary supplement)
Active, not recruiting
- Non-Small-Cell Lung Carcinoma
- Pembrolizumab 200 mg
- +7 more
- (no location specified)
Aug 16, 2022
Lung Cancer Trial in Houston (AMG 510, Cisplatin, Carboplatin)
Recruiting
- Lung Cancer
- AMG 510
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Oct 10, 2022
Non-squamous Non-small-cell Lung Cancer, Brain Metastases Trial in Guangzhou (Camrelizumab, Pemetrexed, Carboplatin)
Active, not recruiting
- Non-squamous Non-small-cell Lung Cancer
- Brain Metastases
- Camrelizumab
- +2 more
-
Guangzhou, Guangzhou, ChinaLi-Kun Chen
Nov 13, 2022
Leptomeningeal Metastasis Trial in Changchun (Pemetrexed, Radiotherapy)
Recruiting
- Leptomeningeal Metastasis
- Pemetrexed
- Radiotherapy
-
Changchun, Jilin, ChinaThe First Hospital of Jilin University
Jun 8, 2022
Adenocarcinoma of Lung, NSCLC Trial in Rolling Meadows (LP-300, Pemetrexed, Carboplatin)
Not yet recruiting
- Adenocarcinoma of Lung
- Carcinoma, Non-Small-Cell Lung
- LP-300
- +2 more
- (no location specified)
Jul 8, 2022
Carcinoma, Non-Small-Cell Lung Trial in Beijing (HLX10, an engineered anti-PD-1 antibody, HLX04, a bevacizumab biosimilar,
Recruiting
- Carcinoma
- Non-Small-Cell Lung
- HLX10, an engineered anti-PD-1 antibody
- +3 more
-
Beijing, Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences (CAMS)
Apr 29, 2022
Non-Small-Cell Lung Carcinoma Trial in Japan (biological, drug, dietary supplement)
Active, not recruiting
- Non-Small-Cell Lung Carcinoma
- Pembrolizumab 200 mg
- +7 more
-
Nagoya, Aichi, Japan
- +9 more
Jan 23, 2023
NSCLC, Mesothelioma, Bladder Cancer Trial in Augusta (Bosutinib, Pemetrexed)
Completed
- Carcinoma, Non-Small-Cell Lung
- +7 more
- Bosutinib
- Pemetrexed
-
Augusta, GeorgiaAugusta University Georgia Cancer Center
Jun 10, 2022
Advanced Lung Non-Small Cell Carcinoma, Non-Small Cell Carcinoma of Lung, TNM Stage 4 Trial in Boston (Granulocyte-Macrophage
Recruiting
- Advanced Lung Non-Small Cell Carcinoma
- Non-Small Cell Carcinoma of Lung, TNM Stage 4
- Granulocyte-Macrophage Colony-Stimulating Factor
- +4 more
-
Boston, MassachusettsTufts Medical Center
Oct 3, 2022
Non-Squamous NSCLC Trial in Shanghai (Sintilimab, IBI305, Pemetrexed)
Recruiting
- Non-Squamous Non-Small Cell Lung Cancer
- Sintilimab
- +5 more
-
Shanghai, Shanghai, ChinaShanghai Chest Hospital
Sep 22, 2022
NSCLC Trial (Durvalumab, Tremelimumab, Pemetrexed)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Durvalumab
- +5 more
- (no location specified)
Aug 17, 2023
NSCLC Trial in Gyeonggi-do, Incheon, Seoul (Lazertinib, Pemetrexed, Carboplatin)
Not yet recruiting
- Non-small Cell Lung Cancer
- Lazertinib
- +2 more
-
Gyeonggi-do, Korea, Republic of
- +5 more
Jul 25, 2022
Non Small Cell Lung Cancer, Mesothelioma Trial in Netherlands (Pemetrexed)
Terminated
- Non Small Cell Lung Cancer
- Mesothelioma
- Pemetrexed
-
's-Hertogenbosch, Netherlands
- +4 more
May 9, 2022
Glioma, Brain Metastases Trial in Shanghai (Autologous progenitor expansion -T, pemetrexed)
Recruiting
- Glioma
- Brain Metastases
- Autologous progenitor expansion -T
- pemetrexed
-
Shanghai, Shanghai, ChinaFudan University Pudong Medical Center
Jul 12, 2022
NSCLC Trial (Bemcentinib, Pembrolizumab, Pemetrexed)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Bemcentinib
- +3 more
- (no location specified)
Jul 19, 2022